Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States
ConclusionPatients with SCD with recurrent VOCs experience substantial clinical and economic burden driven by inpatient costs and frequent VOCs. There is a major unmet need for treatments that alleviate or eliminate clinical complications, including VOCs, and reduce healthcare costs in this patient population. (Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
ConclusionUsing a machine learning approach, patients with moderate-to-severe AD and a BSA affecting 10 –40% and Itch NRS ≥ 7 were characterized as likely to benefit most from BARI 4-mg TCS combination therapy. This was confirmed by subgroup analyses, which showed that these patients are most likely to show favorable response rates in improving AD signs and symptoms, specifically itch, after 16 weeks of treatment. (Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
AbstractThe introduction of novel immunotherapies has transformed the treatment landscape in multiple myeloma (MM). The addition of these agents has significantly improved patient outcomes; however, MM remains largely incurable, with heavily pretreated patients suffering from shorter survival times. To address this unmet need, the focus has shifted toward novel mode of action therapies, such as bispecific antibodies (BsAb), which simultaneously bind to immune effector cells and myeloma cells. Currently, there are several T cell –redirecting BsAb being developed that target BCMA, GPRC5D, and FcRH5. These BsAb show impress...
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
In conclusion, the favorable safety profiles of IL-23 p19 inhibitors support their long-term use in the management of patients with moderate-to-severe psoriasis. (Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
Crossover Randomized Study of Pharmacologic Effects of Ripasudil –Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
ConclusionRBFC significantly reduced IOP compared with each agent alone. A combination of each agent ’s pharmacologic profile was observed in that of RBFC.Trial RegistrationJapan Registry of Clinical Trials; Registration No. jRCT2080225220. (Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review
This article reviews the results of major randomized controlled trials in people with type 2 diabetes that compared iGlarLixi to other therapeutic regimens, representing different intensification strategies, such as basal supported oral therapy, oral antidiabetic drugs, and a combination of the latter with glucagon-like peptide 1 receptor agonists. Moreover, a s a supplement to randomized trials, data from real-world evidence have also been included. (Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
Effect of Nicorandil, Diltiazem, or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts —A Pilot Randomized Controlled Trial (ASRAB-Pilot): Rationale and Study Protocol
ConclusionThis pilot trial will compare the preliminary effects of nicorandil, diltiazem, and isosorbide mononitrate on angiographic and clinical outcomes in patients who have undergone RA-CABG. Recruitment began in June 2020, and the estimated primary completion date is early 2023. Results of this study will provide much needed information for design of large confirmatory trials on the effectiveness of oral antispastic medications after RA-CABG. (Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
BRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
This article has been co-authored by a patient with right-sidedBRAFV600E metastatic colorectal cancer (mCRC), his caregiver, and an oncologist. Here the patient and caregiver discuss their personal experiences struggling with cancer, including their fears, expectations, and attitudes as the disease progresses. The oncologist describes how patients withBRAFV600E mCRC are treated and how the management strategy can be balanced to mitigate any side effects. Improved diagnostic techniques and the availability of numerous treatment options, including various chemotherapy schemes and molecular-targeted drugs, can aid rapid imple...
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
Letter to the Editor Regarding “Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States”
(Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
Study on the Relationship Between Differentially Expressed Proteins in Breast Cancer and Lymph Node Metastasis
ConclusionOur study provides a new perspective for the understanding of the role of DEPs (especially CTGF, EphA2, S100A4, and PRDX2) in the development and metastasis of breast cancer. They could become potential diagnostic and prognostic biomarkers and therapeutic targets. (Source: Advances in Therapy)
Source: Advances in Therapy - July 9, 2023 Category: Drugs & Pharmacology Source Type: research
Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US
ConclusionsAboBoNT-A had the lowest injection visit costs across indications. These results are suggestive of real-world resource utilization patterns and costs, and, while helpful in informing insurers ’ BoNT-A management strategies, further research into cost differences is warranted. (Source: Advances in Therapy)
Source: Advances in Therapy - July 7, 2023 Category: Drugs & Pharmacology Source Type: research
Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study
ConclusionsWe clearly demonstrated that the initial FSH dosage for patients with PCOS undergoing IVF/ICSI with the GnRH-ant protocol may be calculated on the basis of the woman ’s BMI and ovarian reserve markers. The nomogram will help guide clinicians in the selection of the most appropriate initial FSH dose in the future. (Source: Advances in Therapy)
Source: Advances in Therapy - July 3, 2023 Category: Drugs & Pharmacology Source Type: research
Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients
ConclusionWe identified factors associated with a humoral response to a COVID-19 mRNA vaccine in KTRs. These findings might help physicians to optimize vaccination in KTRs. (Source: Advances in Therapy)
Source: Advances in Therapy - July 1, 2023 Category: Drugs & Pharmacology Source Type: research
B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection
The objective of the phase 2b study B-Clear is to access the efficacy and safety of bepirovirsen in participants with chronic HBV in fection.MethodsB-Clear is a phase 2b, multicenter, randomized, partial-blind (sponsor/participant-blinded, investigator-unblinded) study in participants with chronic HBV infection receiving stable nucleos(t)ide analogue (On-NA) or not currently receiving NA therapy (Not-on-NA). Eligibility criteria included HBsAg > 100 IU/mL, HBV DNA < 90 IU/mL (On-NA) or> 2000 IU/mL (Not-on-NA), and alanine aminotransferase ≤ 2 × upper limit of normal (ULN; On-NA) or<...
Source: Advances in Therapy - July 1, 2023 Category: Drugs & Pharmacology Source Type: research
Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study
ConclusionSingle and multiple intravenous infusions of KB at a dose range of 0.06 –0.24 mg/kg are safe and tolerable in healthy volunteers.Trial RegistrationClinicalTrials.gov identifier, NCT02690961. (Source: Advances in Therapy)
Source: Advances in Therapy - June 15, 2023 Category: Drugs & Pharmacology Source Type: research
